Tirzepatide mitigates atherosclerosis progression and modulates oxLDL-mediated proatherogenic effects in macrophages: evidence for M1/M2 homeostasis restoration - PubMed
3 hours ago
- #Atherosclerosis
- #Tirzepatide
- #Macrophage Polarization
- Tirzepatide (TZP), a GLP-1/GIP dual agonist, reduces atherosclerotic burden in apo E-/- mice and improves metabolic parameters.
- TZP inhibits oxLDL-induced foam cell formation and inflammation in macrophages, promoting a shift from pro-inflammatory M1 to anti-inflammatory M2 phenotype.
- The anti-atherosclerotic effects are mediated via the KLF4/PPARγ pathway and may be partially independent of metabolic improvements.